Equashield

Equashield has established itself as a major player in the field of manual and automated technologies for the preparation and administration of hazardous drugs worldwide. Its Closed System Transfer Device (CSTD) offers unprecedented safety and ease of use for healthcare professionals dealing with these potentially harmful substances.

Designed to limit the exposure of hazardous drugs to the outside environment, Equashield CSTDs are clinically recognized for their effectiveness in protecting healthcare workers. The world-renowned Equashield II device stands out for its ability to prevent contamination by drug residues and reduce exposure to vapors emanating from these substances.

Studies have confirmed the superiority of Equashield's CSTDs in terms of speed and ease of use, compared with alternatives available on the market. With a team of 400 employees, the company has also launched Equashield Pro, an innovative solution designed to make automation technologies accessible and easy to integrate into hospital pharmacies.

With a footprint and size comparable to those of a standard biological safety cabinet, Equashield Pro enables efficient and accurate preparation of patient-specific chemotherapy doses. Its verification software reduces the risk of incidents and errors when handling hazardous drugs.

With sales growing steadily, reaching 105 million euros by 2022, Equashield confirms its position as a leader in its field, demonstrating its ability to meet the growing need for safety in the handling of sensitive medical substances.